NCT00216047 - PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions

Breast Cancer

Interventions

DRUG

PTK787

PTK787 daily

DRUG

Trastuzumab

Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle\*

Trial Locations (8)

Indiana University Cancer Center, Indianapolis

Elkhart Clinic, Elkhart

Center for Cancer Care at Goshen Health System, Goshen

Northern Indiana Cancer Research Consortium, South Bend

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

Medical Consultants, P.C., Muncie

AP&S Clinic, Terre Haute

Arnett Cancer Care, Lafayette